OneMedNet Corp

For the period ended Dec 31, 2023. Filed Apr 9, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 9, 2024

ONMD$6.00+16.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

	Year Ended
	2023	2022
Revenue	$1,021,651	$1,152,738
Cost of Revenue	1,149,551	1,513,428
Gross Margin	(127,900)	(360,690)
Operating Expenses
General and administrative	5,273,503	8,755,620
Operations	226,257	398,760
Sales & Marketing	1,114,977	957,690
Research and development	1,631,613	952,701
Total Operating Expenses	8,246,350	11,064,771
Operating loss	(8,374,250)	(11,425,461)
Other Expense (income)
Impairment	10,504,327
Income tax provision	-	214,850
Interest expense	749,213	403,307
Other expense	52,256	46,820
Change in FV of Warrants	(46,822)	(4,489,110)
Stock Expense	3,572,232
Unrealized gain or loss	-	(1,371,689)
Other Expense (income)	14,831,206	(5,195,822)
Net loss	$(23,205,456)	$(6,229,639)
Loss per share of Common Stock:(1)
Basic and Diluted	$(0.98)	N/M
Weighted-average shares of Common Stock outstanding:
Basic and Diluted	23,572,232	N/M

(1)

Loss per share information has not been presented for periods prior to the Business Combination (as defined in Note 3, Business Combination), as it resulted in values that would not be meaningful to the users of these consolidated financial statements. Refer to Note 3, Business Combination for further information. This has been indicated on these statements of operations as “N/M”.

The accompanying notes are an integral part of these consolidated financial statements

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.